Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Lexicon Pharmaceuticals (LXRX) over the last 16 years, with Dec 2024 value amounting to $238.3 million.

  • Lexicon Pharmaceuticals' Cash from Financing Activities fell 77.02% to $36.8 million in Q4 2012 from the same period last year, while for Dec 2012 it was $36.4 million, marking a year-over-year decrease of 76.84%. This contributed to the annual value of $238.3 million for FY2024, which is 26.81% up from last year.
  • Per Lexicon Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $238.3 million for FY2024, which was up 26.81% from $188.0 million recorded in FY2023.
  • Lexicon Pharmaceuticals' 5-year Cash from Financing Activities high stood at $238.3 million for FY2024, and its period low was -$147.6 million during FY2020.
  • Over the past 3 years, Lexicon Pharmaceuticals' median Cash from Financing Activities value was $188.0 million (recorded in 2023), while the average stood at $189.5 million.
  • As far as peak fluctuations go, Lexicon Pharmaceuticals' Cash from Financing Activities tumbled by 6,532.35% in 2020, and later soared by 526.22% in 2022.
  • Yearly analysis of 5 years shows Lexicon Pharmaceuticals' Cash from Financing Activities stood at -$147.6 million in 2020, then spiked by 115.38% to $22.7 million in 2021, then skyrocketed by 526.22% to $142.2 million in 2022, then skyrocketed by 32.17% to $188.0 million in 2023, then increased by 26.81% to $238.3 million in 2024.